Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer

Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)

(2016) R. Finn et al.   ANNALS OF ONCOLOGY

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

(2016) N. Harbeck et al.   ANNALS OF ONCOLOGY

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)

(2016) K. Matter-Walstra et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract P4-13-05: Safety results of the US expanded access program (EAP) of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) for whom letrozole therapy is deemed appropriate

(2016) V Stearns et al.   CANCER RESEARCH

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer

(2016) Carla L. Alves et al.   CLINICAL CANCER RESEARCH

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

(2016) T. Bell et al.   CURRENT MEDICAL RESEARCH AND OPINION

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

(2016) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

(2016) Sunil Verma et al.   ONCOLOGIST

A Cost-Effectiveness Analysis of Palbociclib and other Aromatase Inhibitors for Treatment of Advanced Breast Cancer

(2016) K Bhattacharya et al.   VALUE IN HEALTH

Efficacy of Palbociclib Combinations Versus Endocrine Therapies in Advanced/ Metastatic Breast Cancer: Network Meta-Analysis

(2016) C Chirila et al.   VALUE IN HEALTH

Network Meta-Analysis Comparing Palbociclib with Chemotherapies For Treatment of Postmenopausal Women With HR+/ HER2- Advanced/ Metastatic Breast Cancer

(2016) FR Wilson et al.   VALUE IN HEALTH

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies

(2015) W. Hu et al.   CLINICAL CANCER RESEARCH

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

60P * MECHANISM OF ACTION FOR COMBINED CDK4/6 AND ER INHIBITION IN ER POSITIVE BREAST CANCER

(2014) M. Koehler et al.   ANNALS OF ONCOLOGY

Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY